TICKERNERD
Menu
CSTLCSTLHealthcare · Diagnostics & Research

CSTL Stock Forecast: Castle Biosciences, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$30
−3.04% on the day

The 9 Wall Street analysts covering Castle Biosciences, Inc. hold a median 12-month price target of $44 — +48.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 13 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$933.3M
Ticker Nerd rank
82 / 100
Median analyst target
$44
Analysts covering
9
Total return, dividends reinvested
1W
−7.5%
1M
+28.1%
YTD
−23.9%
1Y
+49.4%
From 52W high
−31.2%
From 52W low
+63.2%
$18
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CSTL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Castle Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
79
Revisions
77
Volatility
72
Accruals
72
Value
70
Momentum
69
Issuance
48
Size
47
Growth
39

Quality (79): The business earns solid, repeatable profits on what it owns.

Growth (39): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CSTL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CSTL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26CSTLHigh $57Median $44Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $35Median $44High $57

The green dot is the last close — the median target sits +48.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026BTIGMaintainsBuy$40 → $44
25 June 2026Roth CapitalInitiatesBuy$40
25 June 2026Roth CapitalInitiatesBuy—
13 May 2026BTIGMaintainsBuy—
7 May 2026BairdMaintainsOutperform—
20 Apr 2026Canaccord GenuityMaintainsBuy—
27 Feb 2026BairdMaintainsOutperform—
26 Jan 2026GuggenheimMaintainsBuy—
12 Jan 2026Lake StreetMaintainsBuy—
5 Jan 2026GuggenheimMaintainsBuy—
22 Dec 2025Canaccord GenuityMaintainsBuy—
12 Dec 2025BTIGMaintainsBuy—
5 Nov 2025BTIGMaintainsBuy—
4 Nov 2025BairdMaintainsOutperform—
9 Sept 2025Canaccord GenuityMaintainsBuy—
21 May 2025ScotiabankMaintainsSector Outperform—
6 May 2025Canaccord GenuityMaintainsBuy—
6 May 2025Lake StreetMaintainsBuy—
28 Feb 2025BairdMaintainsOutperform—
2 Jan 2025Stephens & Co.ReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CSTL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CSTL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
5
Fundamentals

Castle Biosciences, Inc. (CSTL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.5×

Cheaper than 27% of US stocks

Price / sales
2.6×

Cheaper than 46% of US stocks

Price / book
2.0×

Cheaper than 47% of US stocks

EV / EBITDA
−42.6×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
20.1%

Higher than 70% of US stocks

Earnings growth (YoY)
20.1%

Higher than 59% of US stocks

Gross margin
77.1%

Higher than 89% of US stocks

Operating margin
−3.0%

Higher than 30% of US stocks

Net margin
−5.4%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−4.2%

Higher than 40% of US stocks

Return on assets
−1.4%

Higher than 38% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CSTL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
CSTLCastle Biosciences, Inc.$933.3M
82
OPKOPKO Health, Inc.$1.1B
75
FRNMFreenome, Inc.$1.3B
41
FLGTFulgent Genetics, Inc.$529.7M
43
PSNLPersonalis, Inc.$1.5B
41
NEONeoGenomics, Inc.$2.1B
76
WGSGeneDx Holdings Corp.$2.3B
46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Castle Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CSTL news & analysis

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

MarketBeat · 13 Aug 2026positive

Castle Biosciences reported continued momentum in its core diagnostic franchises during the second quarter. CFO Frank Stokes said the company raised its outlook by more than the amount of its reported beat.

Why it matters — A CSTL watcher would care because an outlook raise tied to core diagnostic momentum suggests strengthening performance in its key melanoma and tissue-based testing products.

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript

Seeking Alpha · 31 July 2026neutral

Castle Biosciences held its Q2 2026 earnings call, with a transcript of the call published by Seeking Alpha.

Why it matters — Earnings calls provide direct updates from management on the company's financial results and operational performance.

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 30 July 2026positive

Castle Biosciences reported a Q2 loss of $0.07 per share, narrower than the consensus estimate of a $0.44 loss, though down from earnings of $0.15 per share a year earlier. The company also topped revenue estimates for the quarter.

Why it matters — The narrower-than-expected loss and revenue beat signal that Castle Biosciences' financial performance exceeded analyst forecasts for the quarter.

Castle Biosciences Q2 Earnings Call Highlights

MarketBeat · 30 July 2026positive

Castle Biosciences reported second-quarter 2026 revenue of $103.5 million, a 20% increase year-over-year, driven by growth in its TissueCypher test and other core offerings. The company raised its full-year revenue outlook to between $365 million and $375 million, up from its prior guidance of $345 million to $355 million.

Why it matters — The revenue beat and raised full-year guidance signal stronger-than-expected demand for Castle's core diagnostic tests, which could influence investor expectations for the company's growth trajectory.

FAQ

Frequently asked questions about CSTL stock

What is the CSTL stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Castle Biosciences, Inc. have a median 12-month price target of $44, with estimates ranging from $35 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CSTL stock a buy right now?

Of the 9 analysts covering Castle Biosciences, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Castle Biosciences, Inc. 82 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CSTL?

As at 13 Aug 2026, Castle Biosciences, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (79 of 100).

Will CSTL stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +48.5% from the last close, and Ticker Nerd's factor model ranks Castle Biosciences, Inc. 82 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CSTL stock forecast for 2030?

No analyst covering Castle Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSTL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $57 over the next 12 months.

How has CSTL stock performed over the past year?

Castle Biosciences, Inc. returned +49.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Castle Biosciences, Inc. do?

Castle Biosciences, Inc. is a molecular diagnostics company that develops and provides innovative gene expression profile tests to guide patient care in oncology and related fields.

What is the latest news on CSTL?

The most recent item we track (MarketBeat, 13 Aug 2026): "Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction". Castle Biosciences reported continued momentum in its core diagnostic franchises during the second quarter. CFO Frank Stokes said the company raised its outlook by more than the amount of its reported beat.

Company

About Castle Biosciences, Inc.

Castle Biosciences, Inc. is a molecular diagnostics company that develops and provides innovative gene expression profile tests to guide patient care in oncology and related fields. Its portfolio includes DecisionDx-Melanoma, a risk stratification test predicting metastasis risk in cutaneous melanoma patients; DecisionDx-SCC for assessing recurrence and metastasis risk in cutaneous squamous cell carcinoma; DecisionDx-UM for uveal melanoma metastasis risk; MyPath Melanoma, a diagnostic tool for challenging melanoma cases; and TissueCypher for evaluating progression risk in Barrett’s esophagus patients. These tests support clinical decisions in dermatologic cancers, esophageal conditions, and uveal melanoma by offering personalized risk assessments that inform treatment pathways. Castle Biosciences, Inc. focuses on areas where precise diagnostics can improve outcomes, such as identifying low-risk patients to avoid overtreatment and high-risk individuals for intensified monitoring. Founded in 2008 and headquartered in Friendswood, Texas, the company operates at the intersection of precision medicine and healthcare, delivering tests that enhance decision-making for physicians and patients across these specialized medical domains.

CEO Mr. Derek J. Maetzold · 1,002 employees · United States · https://castlebiosciences.com